|
1
|
Ortiz MV and Dunkel IJ: Retinoblastoma. J
Child Neurol. 31:227–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalsoom S, Wasim M, Afzal S, Shahzad MS,
Ramzan S, Awan AR, Anjum AA and Ramzan K: Alterations in the RB1
gene in Pakistani patients with retinoblastoma using direct
sequencing analysis. Mol Vis. 21:1085–1092. 2015.PubMed/NCBI
|
|
3
|
Busch M, Große-Kreul J, Wirtz JJ, Beier M,
Stephan H, Royer-Pokora B, Metz K and Dünker N: Reduction of the
tumorigenic potential of human retinoblastoma cell lines by TFF1
overexpression involves p53/caspase signaling and miR-18a
regulation. Int J Cancer. 141:549–560. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chu WK, Law KS, Chan SO, Yam JC, Chen LJ,
Zhang H, Cheung HS, Block NL, Schally AV and Pang CP: Antagonists
of growth hormone-releasing hormone receptor induce apoptosis
specifically in retinoblastoma cells. Proc Natl Acad Sci USA.
113:14396–14401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mihanfar A, Fattahi A and Nejabati HR:
MicroRNA-mediated drug resistance in ovarian cancer. J Cell
Physiol. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedrich M, Pracht K, Mashreghi MF, Jäck
HM, Radbruch A and Seliger B: The role of the miR-148/−152 family
in physiology and disease. Eur J Immunol. 47:2026–2038. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chandra S, Vimal D, Sharma D, Rai V, Gupta
SC and Chowdhuri DK: Role of miRNAs in development and disease:
Lessons learnt from small organisms. Life Sci. 185:8–14. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fabbri M: MicroRNAs and cancer: Towards a
personalized medicine. Curr Mol Med. 13:751–756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ceppi P and Peter ME: MicroRNAs regulate
both epithelial-to-mesenchymal transition and cancer stem cells.
Oncogene. 33:269–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CY, Chang JT, Ho YF and Shyu AB:
MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by
silencing HMGA1 and MALT1. Nucleic Acids Res. 44:3772–3787. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martin J, Bryar P, Mets M, Weinstein J,
Jones A, Martin A, Vanin EF, Scholtens D, Costa FF, Soares MB and
Laurie NA: Differentially expressed miRNAs in retinoblastoma. Gene.
512:294–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang JC, Babak T, Corson TW, Chua G, Khan
S, Gallie BL, Hughes TR, Blencowe BJ, Frey BJ and Morris QD: Using
expression profiling data to identify human microRNA targets. Nat
Methods. 4:1045–1049. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao JJ, Yang J, Lin J, Yao N, Zhu Y,
Zheng J, Xu J, Cheng JQ, Lin JY and Ma X: Identification of miRNAs
associated with tumorigenesis of retinoblastoma by miRNA microarray
analysis. Childs Nerv Syst. 25:13–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chakravarthi BV, Goswami MT, Pathi SS,
Robinson AD, Cieślik M, Chandrashekar DS, Agarwal S, Siddiqui J,
Daignault S, Carskadon SL, et al: MicroRNA-101 regulated
transcriptional modulator SUB1 plays a role in prostate cancer.
Oncogene. 35:6330–6340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Han C, Zhu H, Song K and Wu T:
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting
vascular endothelial growth factor (VEGF). Am J Pathol.
182:1629–1639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Strillacci A, Griffoni C, Sansone P,
Paterini P, Piazzi G, Lazzarini G, Spisni E, Pantaleo MA, Biasco G
and Tomasi V: MiR-101 downregulation is involved in
cyclooxygenase-2 overexpression in human colon cancer cells. Exp
Cell Res. 315:1439–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, He X, Liu Y, Zhang H, Chen H, Guo
S and Liang Y: MiR-101-3p inhibits the growth and metastasis of
non-small cell lung cancer through blocking PI3K/AKT signal pathway
by targeting MALAT-1. Biomed Pharmacother. 93:1065–1073. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khan M, Walters LL, Li Q, Thomas DG,
Miller JM, Zhang Q, Sciallis AP, Liu Y, Dlouhy BJ, Fort PE, et al:
Characterization and pharmacologic targeting of EZH2, a fetal
retinal protein and epigenetic regulator, in human retinoblastoma.
Lab Invest. 95:1278–1290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ganguly A and Shields CL: Differential
gene expression profile of retinoblastoma compared to normal
retina. Mol Vis. 16:1292–1303. 2010.PubMed/NCBI
|
|
23
|
Zhang Y, Wu D, Xia F, Xian H, Zhu X, Cui H
and Huang Z: Downregulation of HDAC9 inhibits cell proliferation
and tumor formation by inducing cell cycle arrest in
retinoblastoma. Biochem Biophys Res Commun. 473:600–606. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castro-Magdonel BE, Orjuela M, Camacho J,
García-Chéquer AJ, Cabrera-Muñoz L, Sadowinski-Pine S,
Durán-Figueroa N, Orozco-Romero MJ, Velázquez-Wong AC,
Hernández-Ángeles A, et al: miRNome landscape analysis reveals a 30
miRNA core in retinoblastoma. BMC Cancer. 17:4582017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Montoya V, Fan H, Bryar PJ, Weinstein JL,
Mets MB, Feng G, Martin J, Martin A, Jiang H and Laurie NA: Novel
miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma
proliferation. PLoS One. 10:e01383662015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sheng Y, Ding S, Chen K, Chen J, Wang S,
Zou C, Zhang J, Cao Y, Huang A and Tang H: Functional analysis of
miR-101-3p and Rap1b involved in hepatitis B virus-related
hepatocellular carcinoma pathogenesis. Biochem Cell Biol.
92:152–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan K, Tian J, Shi W, Xia H and Zhu Y:
LncRNA SNHG6 is associated with poor prognosis of gastric cancer
and promotes cell proliferation and EMT through epigenetically
silencing p27 and sponging miR-101-3p. Cell Physiol Biochem.
42:999–1012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin CW, Chang YL, Chang YC, Lin JC, Chen
CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM and Yang PC:
MicroRNA-135b promotes lung cancer metastasis by regulating
multiple targets in the Hippo pathway and LZTS1. Nat Commun.
4:18772013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um
M, Udolph G, Yang H, Lim B and Lodish HF: MicroRNA-125b promotes
neuronal differentiation in human cells by repressing multiple
targets. Mol Cell Biol. 29:5290–5305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuzmichev A, Jenuwein T, Tempst P and
Reinberg D: Different EZH2-containing complexes target methylation
of histone H1 or nucleosomal histone H3. Mol Cell. 14:183–193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hansen KH, Bracken AP, Pasini D, Dietrich
N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M and Helin K: A
model for transmission of the H3K27me3 epigenetic mark. Nat Cell
Biol. 10:1291–1300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fluge Ø, Gravdal K, Carlsen E, Vonen B,
Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM,
et al: Expression of EZH2 and Ki-67 in colorectal cancer and
associations with treatment response and prognosis. Br J Cancer.
101:1282–1289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lian R, Ma H, Wu Z, Zhang G, Jiao L, Miao
W, Jin Q, Li R, Chen P, Shi H and Yu W: EZH2 promotes cell
proliferation by regulating the expression of RUNX3 in laryngeal
carcinoma. Mol Cell Biochem. 439:35–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mohammad F, Weissmann S, Leblanc B, Pandey
DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT,
et al: EZH2 is a potential therapeutic target for H3K27M-mutant
pediatric gliomas. Nat Med. 23:483–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rastogi B, Raut SK, Panda NK, Rattan V,
Radotra BD and Khullar M: Overexpression of HDAC9 promotes oral
squamous cell carcinoma growth, regulates cell cycle progression,
and inhibits apoptosis. Mol Cell Biochem. 415:183–196. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao YX, Wang YS, Cai QQ, Wang JQ and Yao
WT: Up-regulation of HDAC9 promotes cell proliferation through
suppressing p53 transcription in osteosarcoma. Int J Clin Exp Med.
8:11818–11823. 2015.PubMed/NCBI
|
